| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholangitis, Sclerosing | 7 | 2023 | 179 | 1.900 |
Why?
|
| Liver Cirrhosis, Biliary | 4 | 2023 | 108 | 1.030 |
Why?
|
| Cholangitis | 4 | 2022 | 110 | 0.900 |
Why?
|
| Cholangiocarcinoma | 2 | 2021 | 563 | 0.720 |
Why?
|
| Bile Duct Neoplasms | 2 | 2021 | 617 | 0.710 |
Why?
|
| Bezafibrate | 1 | 2019 | 14 | 0.660 |
Why?
|
| Cholestasis | 3 | 2022 | 385 | 0.580 |
Why?
|
| Liver Diseases | 6 | 2020 | 1307 | 0.540 |
Why?
|
| Ursodeoxycholic Acid | 4 | 2023 | 81 | 0.490 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2021 | 304 | 0.440 |
Why?
|
| Antimony Potassium Tartrate | 1 | 2012 | 3 | 0.420 |
Why?
|
| Liver | 10 | 2021 | 7575 | 0.410 |
Why?
|
| Liver Function Tests | 4 | 2020 | 527 | 0.370 |
Why?
|
| Poisoning | 1 | 2012 | 252 | 0.360 |
Why?
|
| Liver Transplantation | 9 | 2023 | 2399 | 0.340 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2012 | 173 | 0.330 |
Why?
|
| Bile Acids and Salts | 3 | 2007 | 398 | 0.320 |
Why?
|
| Fatty Liver | 3 | 2023 | 807 | 0.280 |
Why?
|
| Bile Duct Diseases | 1 | 2006 | 98 | 0.250 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2014 | 2331 | 0.240 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2005 | 112 | 0.240 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2007 | 515 | 0.230 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 12774 | 0.230 |
Why?
|
| Autoimmune Diseases | 5 | 2018 | 2260 | 0.220 |
Why?
|
| Hepatitis B | 1 | 2009 | 707 | 0.220 |
Why?
|
| Liver Abscess | 1 | 2003 | 81 | 0.210 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2019 | 96 | 0.190 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2021 | 25 | 0.190 |
Why?
|
| Liver Neoplasms | 3 | 2014 | 4362 | 0.190 |
Why?
|
| Klebsiella Infections | 1 | 2003 | 145 | 0.190 |
Why?
|
| Alagille Syndrome | 1 | 2001 | 45 | 0.190 |
Why?
|
| Antiviral Agents | 2 | 2014 | 3063 | 0.180 |
Why?
|
| Dyskeratosis Congenita | 1 | 2021 | 70 | 0.180 |
Why?
|
| Klebsiella pneumoniae | 1 | 2003 | 252 | 0.180 |
Why?
|
| Alkaline Phosphatase | 2 | 2023 | 865 | 0.180 |
Why?
|
| Colonic Pseudo-Obstruction | 1 | 2000 | 7 | 0.180 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2000 | 144 | 0.170 |
Why?
|
| Transaminases | 1 | 2000 | 199 | 0.160 |
Why?
|
| Hepatitis C, Chronic | 2 | 2014 | 1031 | 0.160 |
Why?
|
| Liver Cirrhosis | 4 | 2023 | 1950 | 0.150 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2000 | 174 | 0.150 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2006 | 1126 | 0.150 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 1103 | 0.150 |
Why?
|
| PPAR alpha | 1 | 2019 | 177 | 0.150 |
Why?
|
| Hepatitis, Chronic | 1 | 1997 | 53 | 0.140 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2017 | 34 | 0.140 |
Why?
|
| Liver Failure, Acute | 2 | 2012 | 182 | 0.140 |
Why?
|
| Colonic Polyps | 1 | 2001 | 557 | 0.130 |
Why?
|
| Mass Screening | 2 | 2009 | 5455 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 9425 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2021 | 2525 | 0.120 |
Why?
|
| Humans | 52 | 2023 | 768451 | 0.120 |
Why?
|
| Azathioprine | 1 | 1996 | 354 | 0.110 |
Why?
|
| Hepatitis | 1 | 1996 | 228 | 0.110 |
Why?
|
| Consensus | 2 | 2020 | 3207 | 0.110 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2018 | 391 | 0.110 |
Why?
|
| Biological Transport | 2 | 2007 | 2089 | 0.100 |
Why?
|
| Pruritus | 2 | 2023 | 380 | 0.090 |
Why?
|
| Drug Eruptions | 1 | 2014 | 335 | 0.090 |
Why?
|
| Biliary Tract | 1 | 2011 | 135 | 0.090 |
Why?
|
| Tamoxifen | 1 | 1995 | 968 | 0.090 |
Why?
|
| Autoantibodies | 3 | 2012 | 2131 | 0.090 |
Why?
|
| Syndrome | 2 | 2007 | 3278 | 0.080 |
Why?
|
| Referral and Consultation | 2 | 2020 | 3629 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 3665 | 0.080 |
Why?
|
| Endotoxins | 1 | 2011 | 520 | 0.080 |
Why?
|
| Vomiting | 1 | 2012 | 655 | 0.080 |
Why?
|
| Genotype | 1 | 2023 | 13047 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2014 | 1193 | 0.080 |
Why?
|
| Jaundice | 1 | 2009 | 95 | 0.080 |
Why?
|
| Glucocorticoids | 2 | 1997 | 2170 | 0.080 |
Why?
|
| Motion Sickness | 1 | 1988 | 33 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 7451 | 0.080 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2009 | 294 | 0.070 |
Why?
|
| Cholangiography | 1 | 2008 | 182 | 0.070 |
Why?
|
| Audiovisual Aids | 1 | 1988 | 99 | 0.070 |
Why?
|
| Middle Aged | 25 | 2020 | 223418 | 0.070 |
Why?
|
| Critical Care | 1 | 2000 | 2717 | 0.070 |
Why?
|
| Immunoglobulin G | 2 | 2009 | 4572 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 36840 | 0.070 |
Why?
|
| Abdominal Pain | 1 | 1993 | 1070 | 0.070 |
Why?
|
| Multiple Organ Failure | 1 | 2009 | 387 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 749 | 0.070 |
Why?
|
| Paraproteinemias | 1 | 2009 | 254 | 0.070 |
Why?
|
| Mesenteric Veins | 1 | 2006 | 87 | 0.060 |
Why?
|
| Male | 26 | 2020 | 364781 | 0.060 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2008 | 290 | 0.060 |
Why?
|
| Female | 26 | 2021 | 396943 | 0.060 |
Why?
|
| Hepatitis B virus | 1 | 2009 | 530 | 0.060 |
Why?
|
| Biliary Atresia | 1 | 2005 | 88 | 0.060 |
Why?
|
| Varicose Veins | 1 | 2006 | 157 | 0.060 |
Why?
|
| Tissue Donors | 3 | 2020 | 2377 | 0.060 |
Why?
|
| Liver, Artificial | 1 | 2004 | 55 | 0.060 |
Why?
|
| Adult | 20 | 2020 | 223542 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 5532 | 0.060 |
Why?
|
| Morbidity | 1 | 2009 | 1760 | 0.050 |
Why?
|
| Cholagogues and Choleretics | 1 | 2023 | 39 | 0.050 |
Why?
|
| Diagnosis, Differential | 4 | 2012 | 13026 | 0.050 |
Why?
|
| Immunosuppressive Agents | 2 | 2015 | 4213 | 0.050 |
Why?
|
| Cadaver | 2 | 2004 | 1362 | 0.050 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2006 | 568 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2012 | 1802 | 0.050 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2006 | 212 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3116 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2012 | 2396 | 0.050 |
Why?
|
| Pancreatitis | 1 | 2009 | 1087 | 0.050 |
Why?
|
| Pregnancy Complications | 3 | 2006 | 2969 | 0.050 |
Why?
|
| Acetates | 1 | 2023 | 318 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2021 | 54914 | 0.050 |
Why?
|
| Prognosis | 4 | 2020 | 30028 | 0.050 |
Why?
|
| Heterozygote | 2 | 2005 | 2792 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2011 | 3048 | 0.040 |
Why?
|
| Intestine, Small | 1 | 2006 | 1218 | 0.040 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2023 | 635 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2006 | 887 | 0.040 |
Why?
|
| Immunohistochemistry | 4 | 2017 | 11138 | 0.040 |
Why?
|
| Hypertension, Portal | 1 | 2002 | 229 | 0.040 |
Why?
|
| Remission Induction | 2 | 2015 | 2408 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2011 | 3697 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2011 | 3080 | 0.040 |
Why?
|
| Pericardium | 1 | 2023 | 679 | 0.040 |
Why?
|
| Exercise Tolerance | 1 | 2004 | 849 | 0.040 |
Why?
|
| Biopsy, Needle | 2 | 2017 | 1629 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 9263 | 0.040 |
Why?
|
| gamma-Globulins | 1 | 1997 | 119 | 0.040 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2012 | 2444 | 0.040 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2023 | 1095 | 0.040 |
Why?
|
| Decision Support Techniques | 2 | 2004 | 2010 | 0.040 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 15460 | 0.030 |
Why?
|
| Receptors, Cholecystokinin | 1 | 1996 | 18 | 0.030 |
Why?
|
| Gastrins | 1 | 1996 | 75 | 0.030 |
Why?
|
| Osteoporosis | 1 | 2006 | 1606 | 0.030 |
Why?
|
| Tissue and Organ Procurement | 1 | 2004 | 983 | 0.030 |
Why?
|
| Hemochromatosis | 1 | 1997 | 176 | 0.030 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 15965 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2020 | 1421 | 0.030 |
Why?
|
| Treatment Outcome | 7 | 2023 | 65409 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2019 | 8730 | 0.030 |
Why?
|
| Time | 1 | 2017 | 546 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2008 | 5995 | 0.030 |
Why?
|
| Biopsy | 2 | 2015 | 6816 | 0.030 |
Why?
|
| Pregnancy | 3 | 2006 | 30179 | 0.030 |
Why?
|
| Observer Variation | 1 | 2020 | 2622 | 0.030 |
Why?
|
| North America | 1 | 2017 | 1292 | 0.030 |
Why?
|
| Sodium | 1 | 2019 | 1595 | 0.030 |
Why?
|
| Occupational Health | 1 | 2020 | 814 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 3543 | 0.030 |
Why?
|
| Gastroenterology | 1 | 2020 | 588 | 0.030 |
Why?
|
| Disease Progression | 2 | 2023 | 13655 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2019 | 1532 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2019 | 6353 | 0.030 |
Why?
|
| Abortion, Habitual | 1 | 1993 | 61 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 13708 | 0.030 |
Why?
|
| Colchicine | 1 | 1993 | 258 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2019 | 1412 | 0.020 |
Why?
|
| Echocardiography | 1 | 2023 | 5043 | 0.020 |
Why?
|
| Risk Factors | 3 | 2020 | 74915 | 0.020 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2011 | 80 | 0.020 |
Why?
|
| Aged | 10 | 2019 | 171520 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2022 | 3708 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 1734 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2011 | 1553 | 0.020 |
Why?
|
| Markov Chains | 2 | 2004 | 977 | 0.020 |
Why?
|
| Acute Disease | 1 | 2000 | 7246 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 876 | 0.020 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2009 | 100 | 0.020 |
Why?
|
| Iron | 1 | 1997 | 1813 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 4861 | 0.020 |
Why?
|
| Young Adult | 3 | 2021 | 60045 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2011 | 705 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2011 | 23638 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2023 | 9507 | 0.020 |
Why?
|
| Survival Analysis | 3 | 2004 | 10125 | 0.020 |
Why?
|
| Exercise | 1 | 2004 | 5940 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2019 | 3458 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2019 | 24311 | 0.020 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2006 | 64 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 3922 | 0.020 |
Why?
|
| Boston | 1 | 2019 | 9361 | 0.020 |
Why?
|
| Video-Assisted Surgery | 1 | 2006 | 51 | 0.020 |
Why?
|
| Animals | 4 | 2007 | 169418 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2009 | 598 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 12096 | 0.020 |
Why?
|
| Hepatectomy | 1 | 2009 | 588 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 4049 | 0.020 |
Why?
|
| Comorbidity | 1 | 2020 | 10601 | 0.020 |
Why?
|
| Phlebography | 1 | 2006 | 326 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 10784 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2019 | 5103 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2009 | 1869 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 4586 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3816 | 0.010 |
Why?
|
| Steroids | 1 | 2009 | 937 | 0.010 |
Why?
|
| Dermatology | 1 | 2014 | 920 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2011 | 5042 | 0.010 |
Why?
|
| Portal Vein | 1 | 2006 | 432 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 2004 | 318 | 0.010 |
Why?
|
| Microscopy | 1 | 1988 | 909 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 20231 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2011 | 2491 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 14728 | 0.010 |
Why?
|
| United States | 2 | 2009 | 73121 | 0.010 |
Why?
|
| Age Factors | 1 | 2019 | 18478 | 0.010 |
Why?
|
| Bilirubin | 1 | 2004 | 439 | 0.010 |
Why?
|
| Patient Selection | 2 | 2004 | 4266 | 0.010 |
Why?
|
| Sigmoid Neoplasms | 1 | 2002 | 53 | 0.010 |
Why?
|
| Mutation | 1 | 2006 | 30243 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2011 | 5904 | 0.010 |
Why?
|
| Prevalence | 1 | 2017 | 15880 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8753 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 4362 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2020 | 5952 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2004 | 1262 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2004 | 1697 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 59680 | 0.010 |
Why?
|
| Living Donors | 1 | 2001 | 651 | 0.010 |
Why?
|
| Adolescent | 3 | 2004 | 89168 | 0.010 |
Why?
|
| Transferrin | 1 | 1997 | 285 | 0.010 |
Why?
|
| Models, Biological | 1 | 1993 | 9505 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 26351 | 0.010 |
Why?
|
| Equipment Design | 1 | 2004 | 3530 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 39430 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 2002 | 1176 | 0.010 |
Why?
|
| Ferritins | 1 | 1997 | 601 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2001 | 1249 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2017 | 41797 | 0.010 |
Why?
|
| Time Factors | 1 | 2015 | 40271 | 0.010 |
Why?
|
| Danazol | 1 | 1993 | 44 | 0.010 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 1993 | 72 | 0.010 |
Why?
|
| Homozygote | 1 | 1997 | 1779 | 0.010 |
Why?
|
| Xenopus laevis | 1 | 1996 | 966 | 0.010 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 1993 | 108 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 1 | 1993 | 343 | 0.010 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1993 | 167 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2012 | 81834 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2004 | 11249 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 12561 | 0.010 |
Why?
|
| Isoantibodies | 1 | 1993 | 682 | 0.000 |
Why?
|
| Fetal Growth Retardation | 1 | 1993 | 585 | 0.000 |
Why?
|
| Spermatozoa | 1 | 1993 | 631 | 0.000 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1993 | 672 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 1995 | 21156 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1996 | 3735 | 0.000 |
Why?
|
| Binding Sites | 1 | 1996 | 6030 | 0.000 |
Why?
|
| Survival Rate | 1 | 2001 | 12875 | 0.000 |
Why?
|
| Heparin | 1 | 1993 | 1636 | 0.000 |
Why?
|
| Base Sequence | 1 | 1996 | 12428 | 0.000 |
Why?
|
| Fetus | 1 | 1993 | 1883 | 0.000 |
Why?
|
| Fertilization in Vitro | 1 | 1993 | 1297 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1996 | 13452 | 0.000 |
Why?
|
| Endometriosis | 1 | 1993 | 873 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 17647 | 0.000 |
Why?
|
| Histones | 1 | 1993 | 2595 | 0.000 |
Why?
|
| Hypertension | 1 | 1993 | 8611 | 0.000 |
Why?
|
| Mice | 1 | 1993 | 82045 | 0.000 |
Why?
|